 VIRAL-MC21-1 Demonstrates Stability of DehydraTECHTM-Enabled Antiviral Drugs KELOWNA, BC ACCESSWIRE July 15, 2021 Lexaria Bioscience Corp. NASDAQ:LEXXNASDAQ:LEXXW the Company or Lexaria, a global innovator in drug delivery platforms is pleased to announce results from its antiviral drug molecular characterization study VIRAL-MC21-1 recently completed by Canadas premier federally funded research organization, the National Research Council NRC. The NRC has successfully confirmed Lexarias study objectives, demonstrating DehydraTECHTM processing and formulation technology does not create a covalently bonded new molecular entity NME and that each drug tested remained stable and did not undergo change in chemical structure. 